HomeNewsBusinessShriram Transport Finance hires 8 bankers for a Rs 1,500 crore rights issue

Shriram Transport Finance hires 8 bankers for a Rs 1,500 crore rights issue

The firm seeks to improve its capital adequacy ratio and debt-to-equity ratio and boost its lending business through this rights issue.

June 23, 2020 / 14:03 IST
Story continues below Advertisement

Commercial vehicle financier Shriram Transport Finance Co Ltd (STFC), the flagship entity of Chennai-headquartered Shriram Group, has engaged eight merchant bankers to launch a Rs 1,500 crore rights issue and prepare for any COVID-19 related uncertainties, sources in the know told Moneycontrol.

This is the firm’s first attempt in a decade to raise funds via equity markets. Ajay Piramal-led Piramal Group owns 20 percent stake in Shriram Capital, which in turn holds around 26 percent in STFC.

Story continues below Advertisement

“The kick-off for the proposed rights issue took place on June 22 and the firm has shortlisted JP Morgan, ICICI Securities, HSBC, BNP Paribas, Citi, Credit Suisse, SBI Capital and Axis Capital as merchant bankers,” one of the persons cited above said.

The plan is to launch the rights issue in the next few weeks and close the deal before July end, he added. A second person confirmed the names of the shortlisted merchant bankers and the launch timeline.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show